Table 2.
The distribution of non-SARS-CoV-2 mono-infections (RV—rhinovirus, HAdV—human adenovirus, HMPV—human metapneumovirus, EV—enterovirus, and FLUV—influenza virus) and all co-infections caused by SARS-CoV-2 and other respiratory viruses.
| Age Group | Mono-Infections, n (Female/Male) | Co-Infections, n (Female/Male) |
|---|---|---|
| RV | SARS-CoV-2 + RV | |
| Total | 22 (13/9) | 13 (9/4) |
| 0–5 | 2 (2/0) | 2 (0/2) |
| 6–18 | 2 (0/2) | 0 (0/0) |
| 19–35 | 6 (3/3) | 2 (2/0) |
| 36–64 | 11 (7/4) | 7 (6/1) |
| ≥65 | 1 (1/0) | 2 (1/1) |
| HAdV | SARS-CoV-2 + HAdV | |
| Total | 0 (0/0) | 2 (2/0) |
| 0–5 | 0 (0/0) | 0 (0/0) |
| 6–18 | 0 (0/0) | 1 (1/0) |
| 19–35 | 0 (0/0) | 0 (0/0) |
| 36–64 | 0 (0/0) | 1 (1/0) |
| ≥65 | 0 (0/0) | 0 (0/0) |
| HMPV | SARS-CoV-2 + HMPV | |
| Total | 10 (6/4) | 2 (1/1) |
| 0–5 | 0 (0/0) | 0 (0/0) |
| 6–18 | 0 (0/0) | 0 (0/0) |
| 19–35 | 3 (2/1) | 0 (0/0) |
| 36–64 | 5 (3/2) | 2 (1/1) |
| ≥65 | 2 (2/0) | 0 (0/0) |
| EV | RV + EV | |
| Total | 0 (0/0) | 1 (0/1) |
| ≥65 | 0 (0/0) | 1 (0/1) |
| FLUV | ||
| Total | 1 (1/0) | - |
| 36–64 | 1 (1/0) | - |